{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+treatment+to+blind+study&page=3",
    "query": {
      "intervention": "Placebo treatment to blind study",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 6460,
    "total_pages": 646,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+treatment+to+blind+study&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+treatment+to+blind+study&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T13:18:28.839Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06601192",
      "title": "A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "RSV Infection",
        "QTc Interval"
      ],
      "interventions": [
        {
          "name": "zelicapavir (therapeutic dose)",
          "type": "DRUG"
        },
        {
          "name": "zelicapavir (supratherapeutic dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Enanta Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 72,
      "start_date": "2024-07-15",
      "completion_date": "2025-02-25",
      "has_results": false,
      "last_update_posted_date": "2025-07-28",
      "last_synced_at": "2026-10-09T13:18:28.839Z",
      "location_count": 2,
      "location_summary": "Lenexa, Kansas • San Antonio, Texas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06601192"
    },
    {
      "nct_id": "NCT04003636",
      "title": "Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Biliary Tract Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1069,
      "start_date": "2019-09-24",
      "completion_date": "2025-04-01",
      "has_results": true,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-10-09T13:18:28.839Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04003636"
    },
    {
      "nct_id": "NCT03369236",
      "title": "A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "C3 Glomerulopathy",
        "C3 Glomerulonephritis",
        "Dense Deposit Disease"
      ],
      "interventions": [
        {
          "name": "Danicopan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "17 Years to 65 Years"
      },
      "enrollment_count": 13,
      "start_date": "2018-06-12",
      "completion_date": "2020-12-18",
      "has_results": true,
      "last_update_posted_date": "2022-10-14",
      "last_synced_at": "2026-10-09T13:18:28.839Z",
      "location_count": 6,
      "location_summary": "Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03369236"
    },
    {
      "nct_id": "NCT06003777",
      "title": "A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "PF-06954522",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 26,
      "start_date": "2023-08-30",
      "completion_date": "2024-02-20",
      "has_results": true,
      "last_update_posted_date": "2025-06-24",
      "last_synced_at": "2026-10-09T13:18:28.839Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06003777"
    },
    {
      "nct_id": "NCT02035267",
      "title": "Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Moderate to Severe Convexity of Submental Fat",
        "Safety",
        "Efficacy"
      ],
      "interventions": [
        {
          "name": "Deoxycholic Acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kythera Biopharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 93,
      "start_date": "2014-01",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-10-09T13:18:28.839Z",
      "location_count": 8,
      "location_summary": "Newport Beach, California • San Francisco, California • West Hollywood, California + 5 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "West Hollywood",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02035267"
    },
    {
      "nct_id": "NCT00638807",
      "title": "Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Osteoarthritis, Knee"
      ],
      "interventions": [
        {
          "name": "Celecoxib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 388,
      "start_date": "2003-12",
      "completion_date": "2004-07",
      "has_results": false,
      "last_update_posted_date": "2021-02-02",
      "last_synced_at": "2026-10-09T13:18:28.839Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • Buena Park, California • Denver, Colorado + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Longwood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00638807"
    },
    {
      "nct_id": "NCT01218516",
      "title": "A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Lung"
      ],
      "interventions": [
        {
          "name": "Farletuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Morphotek",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2011-06-27",
      "completion_date": "2013-11-01",
      "has_results": true,
      "last_update_posted_date": "2020-08-20",
      "last_synced_at": "2026-10-09T13:18:28.839Z",
      "location_count": 54,
      "location_summary": "Chandler, Arizona • Glendale, Arizona • Beverly Hills, California + 50 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Gilroy",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01218516"
    },
    {
      "nct_id": "NCT00040404",
      "title": "Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "CEP-1347 10mg",
          "type": "DRUG"
        },
        {
          "name": "CEP1347 25mg",
          "type": "DRUG"
        },
        {
          "name": "CEP-1347 50mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Cephalon",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 806,
      "start_date": "2002-03",
      "completion_date": "2005-08",
      "has_results": false,
      "last_update_posted_date": "2012-05-10",
      "last_synced_at": "2026-10-09T13:18:28.839Z",
      "location_count": 56,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 46 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00040404"
    },
    {
      "nct_id": "NCT04223349",
      "title": "A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "JNJ-70033093",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 66,
      "start_date": "2020-01-10",
      "completion_date": "2020-04-08",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-10-09T13:18:28.839Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04223349"
    },
    {
      "nct_id": "NCT07369115",
      "title": "Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctive Therapy for Major Depressive Disorder and History of Early Life Abuse",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Major Depressive Diorder",
        "Early Life Trauma"
      ],
      "interventions": [
        {
          "name": "Lumateperone 42 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Texas at Austin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "21 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2026-02",
      "completion_date": "2030-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-27",
      "last_synced_at": "2026-10-09T13:18:28.839Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07369115"
    }
  ]
}